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Chemokines were originally identified as mediators of the inflammatory process 
and regulators of leukocyte trafficking. Subsequent studies revealed their essential 
roles in leukocyte physiology and pathology. Moreover, chemokines have profound 
effects on other types of cells associated with the inflammatory response, such as 
endothelial cells and fibroblasts. Thus, chemokines are crucial for cancer-related 
inflammation, which can promote tumor development and progression. Increasing 
evidence points to the vital effects of several chemokines on the proliferative and 
invasive properties of tumor cells. The wide range of activities of chemokines in 
tumorigenesis highlights their roles in tumor development and progression. 
 





Chemokines are a superfamily of heparin-binding proteins and they are 
characterized by the presence of 4 cysteine residues inconserved positions [1]. Two 
intramolecular disulfide bonds are formed between the first and third cysteines, and 
between the second and fourth cysteines, and these bonds result in the formation of 
triple-stranded β-sheet structures [2]. The carboxy-terminal region forms an α-helix 
and has the capacity to bind heparin. Through the carboxy-terminal region, 
chemokines bind to proteoglycans on the vascular endothelium and other cell surfaces, 
and may be immobilized by proteoglycans on endothelial cells and in the extracellular 
matrix proteins. All chemokine receptors are 7-span transmembrane proteins that 
signal mainly through receptor-coupled trimeric G proteins. 
Chemokines are divided into 4 subgroups, namely, CXC, CC, CX 3 C, and C [1]. 
The first 2 cysteines are separated by 1 and 3 amino acids in CXC and CX 3 C 
chemokines, respectively, while the first 2 cysteines are adjacent in CC 
chemokines. The single C chemokine lacks the second and fourth cysteines [1]. 
Systematic chemokine nomenclature is based on their cysteine subclass roots, 
followed by “L” for “ligand” [3]. The numbers correspond to the number used in 
the corresponding gene nomenclature. The CXC chemokines are further grouped 
based on the presence or absence of a 3-amino acid sequence, glutamic 
acid-leucine-arginine (the “ELR” motif), immediately preceding the CXC sequence 
[4]. Because most chemokine receptors can bind to a single chemokine subclass,  
the nomenclature system of chemokine receptors is rooted by the chemokine 
subclass specificity,  followed by “R” for “receptor” and the corresponding 
number [3] (Table).  
The human and mouse chemokine families differ in gene number, and the 
orthologous relationship between them remains ambiguous [5]. A notable difference 
between species has been found in one of the major chemokine, CXCL8, and its 
receptors, CXCR1 and CXCR2. Mice and rats do not possess a homolog of the 
CXCL8/IL-8 gene, which is present in other species, including humans [5]. Moreover, 
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the CXCR1 and CXCR2 genes encode functional receptor proteins in humans, whereas 
no functional CXCR1 has been identified in mice or rats [6]. These findings should be 
taken into consideration when observations obtained with mouse models are 
extrapolated to human situations. 
In the present review, we discuss the potential roles of chemokines in tumor 
development and progression by focusing on their effects on components of tumor 
tissues, including cancer cells, leukocytes, endothelial cells, and fibroblasts. 
 
Direct effects on cancer cells 
The tyrosine kinase, RET, which is a prototypic transforming oncogene in human 
papillary thyroid carcinoma induces the expression of CCL2, CCL20, ELR-positive 
CXC chemokines, and CXCL12 and its receptor, CXCR4 [7]. Moreover, components 
of the Ras-Raf signaling pathway induce the production of CXCL8 by activating 
NF-κB [8]. Constitutive activation of NF-κB induces the expression of chemokines, 
including CXCL1, CXCL8, and CCL2 in various types of tumors [9]. The CXCR4 
gene can further be transactivated by the activation of hypoxia-inducible factor 
(HIF)-1α, arising from either loss of the von-Hippel-Lindau tumor suppressor (VHL) 
or due to the hypoxic conditions observed frequently in tumor tissues [10]. NF-κB and 
HIF are also activated in inflammation, which is frequently associated with 
tumorigenesis [11]. Thus, even in the absence of direct oncogene activation, the 
expression of chemokines and their receptors can be augmented in tumor sites. 
The term “cellular senescence” has been used to denote a stable and long-term loss 
of proliferative capacity, despite continued viability and metabolic activity [12]. 
Cellular senescence can occur in response to the activation of an oncogene. 
Oncogene-induced senescence (OIS) serves as a potent barrier against oncogenic 
transformation by suppressing the unscheduled proliferation of early neoplastic cells 
[12]. Two independent groups reported that cells undergoing OIS secrete 
CXCR2-binding chemokines and IL-6 through the activation of 2 pro-inflammatory 
transcription factors, C/EBP-β and NF-κB [13, 14]. In human colon adenomas, 
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CXCL8/IL-8 specifically colocalizes with arrested p16INK4A-positive epithelium [13]. 
Furthermore, the reduction of CXCR2 expression alleviates OIS and diminishes the 
DNA-damage response, while ectopic expression of CXCR2 results in premature 
senescence via a p53-dependent mechanism [14]. Thus, CXCR2-binding chemokines 
can promote the arrest of cellular growth and eventually delay the early phase of 
tumorigenesis (Figure 1).  
Epithelial-mesenchymal transition (EMT) is a physiological process that occurs 
during embryogenesis [15]. During EMT, epithelial cells lose the expression of 
components of cell polarity, such as E-cadherin, while expressing mesenchymal 
components of the cytoskeleton and acquiring motility and scattering properties. A 
closely related phenotypic conversion is detected in cancer and is associated with the 
capacity of tumor cells to invade and metastasize [15]. In response to prolonged 
exposure to transforming growth factor (TGF)-β, rat hepatoma cells exhibit a 
mesenchymal phenotype, and a higher migratory and invasive capacity, coincident 
with increased CXCR4 expression [16]. The invasive capacity of TGF-β-exposed 
cells is reduced by a CXCR4 antagonist [16]. Likewise, the expression of CXCL8 and 
its receptor, CXCR1, is induced in a human colon cancer cell line undergoing 
TGF-β-driven EMT [17]. Increasing lines of evidence indicate that EMT in cancer 
cells is initiated by overexpression of several transcription factors, including Twist 
and Snail [15]. Overexpression of a T-box transcription factor, Brachyury, also 
induces EMT in human pancreatic cancer cell lines, along with enhanced expression 
of several chemokines, including CXCL8, CCL5, and CXCL1 [18]. The inhibition of 
CXCL8 signaling pathway also abrogates Brachyury-induced EMT phenotypes and 
invasive capacity of cells [18]. These observations suggest that several chemokines 
may play important roles in EMT, which is a necessary step for the malignant 
progression of cancer (Figure 1). 
Chemokine receptor engagement can also activate the mitogen-activated protein 
(MAP)/Erk kinase pathway [19], leading to gene expression and cell proliferation. 
CXCL8 can induce human gastric cancer cell lines, which possess CXCR1 and 
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CXCR2, to express epidermal growth factor (EGF) receptor, matrix metalloproteinase 
(MMP)-9, and vascular endothelial growth factor (VEGF) [20]. The same pathway is 
utilized to promote proliferation of esophageal cancer cells [21] and melanoma cells 
[22]. Accumulating evidence also implicates CXCR4 in the proliferation of various 
cancer cells including ovarian, glioma, melanoma, lung, renal, and thyroid cancer 
cells [23, 24]. The CXCL12/CXCR4 axis delivers surviving signals to hepatoma, 
ovarian, and chronic leukemia cells and CXCR4 blockade induces the apoptosis of 
these malignant cells [16, 25, 26] (Figure 1). CXCL12 expression correlates well with 
lower apoptosis in human myelodysplastic syndrome [27]. Likewise, CCR6 and 
CXCR6 can promote the proliferation of colorectal cancer cells [28] and prostate 
cancer cells [29], respectively. Furthermore, phosphatidylinositol-3-kinase 
(PI3K)-mediated protection of tumor cells from apoptosis has been reported after 
CCR10 activation in melanoma [30] and CCR7 activation in squamous cell carcinoma 
of the head and neck [31] (Figure 1). In contrast, CCR5 blockade can enhance the 
proliferation of breast cancer cells, which express wild-type p53 [32]. This is 
supported by the observation that disease-free survival is shorter in breast cancer 
patients bearing the CCR5∆32 allele with a premature stop codon, than in CCR5 
wild-type patients; this holds true only in wild-type p53-expressing tumors [32]. 
Likewise, human hepatocellular carcinoma (HCC) cells express CCR1 and its ligands 
can reduce the proliferation of human HCC cell lines [33]. 
Circulating tumor cells (CTCs) are presumed to be a source of metastasizing tumor 
cells, but they can also colonize tumors at their original site. This process, which is 
called tumor self-seeding, can accelerate tumor growth and angiogenesis. CTCs 
produce ELR-positive CXC chemokines including CXCL8 and CXCL1, and these 
chemokines eventually promote self-seeding [34]. 
Adult T cell leukemia (ATL) cells are characterized by frequent expression of 
CCR4 and can migrate in vitro to CCL17 and CCL22, which are ligands for CCR4 
[35]. The CCL17/CCL22-CCR4 axis may account for the frequent infiltration of ATL 
into skin and lymph nodes, where CCL17 and CCL22 are abundantly expressed. 
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Humanized monoclonal antibody to CCR4 has been proven to be effective against 
ATL [36]. 
CXCR4 is the most commonly detected chemokine receptor in tumor cells, and 
CXCR4-expressing cells can migrate in vitro towards CXCL12 [26, 27]. CCR7, CCR9, 
CXCR1, and CXCR2 are also detected in tumor cells and their ligands can induce the 
chemotaxis of the corresponding receptor-expressing cells [37-40]. These chemokines 
can serve as inducers of invasion within the primary tumor and dissemination to 
distant organs (Figure 1). 
Several models have been proposed to explain the molecular mechanisms 
underlying the enhancement and regulation of metastasis by these chemokines. Some 
research suggested that specific chemokine receptor-expressing tumor cells migrate to 
organs with high expression levels of the respective chemokines along a concentration 
gradient [37]. This hypothesis may explain the tissue tropism observed in certain 
types of cancer, but there is little evidence to indicate the presence of chemokine 
concentration gradients between primary and metastatic sites. Shields et al. 
demonstrated that a transcellular CCR7 ligand gradient is created when cancer cells 
produce CCR7 ligands under flow conditions and that this resultant gradient is the 
basis of lymphatic metastasis [41]. These observations would indicate that cancer 
cells themselves actively promote their own metastasis and tropism by producing 
chemokines. Another plausible explanation is that the arrival of tumor cells in a 
specific organ is passive and that chemokine receptor expression provides tumor cells 
with an advantage to survive and grow in a different ligand-rich metastatic 
microenvironment [42]. Moreover, CXCL12 and a CCR7 ligand, CCL21, can reduce 
the sensitivity of cancer cells to anoikis, which is believed to be one of the major 
blocks in the metastatic spread of various types of cancer, by regulating pro-apoptotic 
Bmf and anti-apoptotic Bcl-xL proteins [43]. Thus, chemokines may accelerate 
metastasis by promoting tumor cell proliferation or preventing tumor cell death. 
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These findings collectively suggest that chemokines can prevent tumorigenesis in 
the early phase by inducing cellular senescence and can also promote invasion and 
metastasis by enhancing the motility and survival of tumor cells (Figure 1). 
 
Leukocytes 
It is widely acknowledged that leukocytes are localized in both the 
tumor-supporting stroma and the tumor areas and might account for up to 50% of the 
tumor mass, the most predominant subset being macrophages [22, 44]. 
Tumor-associated macrophages (TAMs) are derived mostly from circulating 
monocytes which are attracted into tumor sites, by locally produced chemotactic 
factors, such as CCL2, CCL5, CCL7, CCL8, CXCL12, and macrophage colony 
stimulating factor (M-CSF) [22]. 
Several lines of evidence indicate that CCL2 plays an important role in TAM 
recruitment among these chemotactic factors [22, 44]. Combined treatment with 
azoxymethane and repeated dextran sodium sulfate solution ingestion causes the 
development of multiple tumors in murine colons, together with a massive infiltration 
of monocytes/macrophages expressing cyclooxygenase (COX)-2, an enzyme crucially 
involved in colon carcinogenesis [45]. Abundant CCL2 is detected in colon tissues, 
and it induces CCR2-positive COX-2 expressing monocytes/macrophages to infiltrate 
colon tissues, thereby promoting colon carcinoma development and progression [45]. 
Moreover, CCL2 recruits monocytes to pulmonary metastatic sites of murine breast 
cancer. As a consequence, infiltrated monocytes promote the extravasation of tumor 
cells, a necessary step for metastasis, in a process that requires monocyte-derived 
VEGF [46]. 
TAMs produce various growth factors such as TGF-β and fibroblast growth factor 
(FGF) in addition to VEGF and prostaglandin [22, 44]. Moreover, TAMs exhibit the 
properties of M2-polarized macrophages and express scavenger receptors and the 
mannose receptor [47]. Furthermore, they produce immunosuppressive molecules 
including IL-10, TGF-β, and arginase [47]. These properties endow TAMs with an 
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immunosuppressive capacity. Thus, TAMs can promote tumor progression through 
the production of growth factors and the suppression of adaptive anti-tumor immunity 
(Figure 2). 
Tumor tissues contain additional types of cells that can suppress adaptive immunity. 
One prominent example is myeloid-derived suppressor cells (MDSCs), which are 
characterized by the co-expression of the myeloid-cell lineage differentiation antigen 
Gr-1 and CD11b in the mouse [48]. In humans, MDSCs are defined as CD14-CD11b+ 
cells or as cells that express the common myeloid marker CD33 but lack the 
expression of mature myeloid and lymphoid markers [48]. MDSCs express the 
immunosuppressive enzymes, arginase 1 and inducible NO synthetase (iNOS), and 
produce immunosuppressive cytokines such as TGF-β1 and IL-10, thereby inhibiting 
the T cell response [48]. CCL2 recruits MDSCs in several types of mouse cancer, 
including Lewis lung carcinoma, methA sarcoma, melanoma and lymphoma [49]. 
However, CCR2 deficiency results in the conversion of the MDSC phenotype to 
neutrophil lineage without affecting tumor growth [50].  CXCL5 and CXCL12 also 
induce MDSC infiltration in mouse mammary adenocarcinoma [51] (Figure 2). 
However, the roles of chemokines in MDSC recruitment in human are still poorly 
defined. 
Regulatory T (Treg) cells are physiologically engaged in the maintenance of 
immunological self-tolerance [52]. A large number of Treg cells often infiltrate into 
tumors and systemic removal of Treg cells enhances natural as well as 
vaccine-induced anti-tumor T cell immunity. Treg cells express CCR4, and its ligand, 
CCL22, regulates intratumoral Treg infiltration in various tumors [52]. Hypoxia 
induces the expression of another chemokine, CCL28, in tumor sites. CCL28 
promotes angiogenesis and recruits Treg cells, thereby also propagating immune 
tolerance [53] (Figure 2). 
Anti-tumor responses are attributable to several types of cells infiltrating into a 
tumor site, such as tumor infiltrating lymphocytes (TIL) and dendritic cells [54]. An 
abundance of TILs is a favorable prognostic sign in various human cancers, especially 
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in colorectal cancer [55]. TILs express the chemokine receptor, CXCR3, and the 
corresponding ligands, CXCL9 and CXCL10, can elicit anti-tumor responses, which 
are accompanied by increased infiltration of CD4- and CD8-positive lymphocytes 
[56]. Another chemokine, CXCL16, can also recruit TIL and tumors expressing high 
levels of CXCL16 have slower progression with infiltration of CD4- and 
CD8-positive lymphocytes [57] (Figure 2). The appearance of apoptotic cells induces 
the migration of dendritic cells to the draining lymph nodes and eventually generates 
a specific cytotoxic T lymphocyte population by utilizing the CCL3-CCR5/CCR1 axis 
[58]. 
CCL2 transduction in tumor cells does not enhance but rather retards tumor growth 
in vivo by activating natural killer (NK) cell activity [59]. Transduction of CCL2 may 
result in its expression to a larger extent compared with endogenous production by 
tumor cells, and may thus modulate the functions of NK cells. Thus, chemokines may 
act on different types of cells present in tumor sites and may have different effects on 
tumorigenesis, in a context-dependent manner. 
 
Neovascularization 
Neovascularization is crucial for tumor growth, progression, and metastasis [60]. 
Chemokines have critical roles in tumor neovascularization [61]. The ELR-positive 
CXC chemokines, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 
directly promote the migration and proliferation of endothelial cells and eventually 
neovascularization, mainly by interacting with CXCR2 but not with CXCR1 [62]. 
Although CXCL12 is not an ELR-positive CXC chemokine, it also has potent 
angiogenic effects [36]. In addition, 3 CC chemokines, CCL2, CCL11, and CCL16 
have also been implicated in tumor neovascularization [63-65]. CCR2, a specific 
receptor for CCL2, is expressed by endothelial cells and CCL2 exerts its angiogenic 
activity in a membrane type 1 (MT1)-MMP-dependent manner [63] (Figure 2). 
CXCL4 and interferon-inducible ELR-negative CXC chemokines such as CXCL9, 
CXCL10, and CXCL11 inhibit the angiogenesis induced by ELR-positive CXC 
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chemokines, VEGF, and bFGF [66, 67]. The anti-angiogenic effects of these 
chemokines are mediated by a common receptor, CXCR3 (Figure 2). Moreover, the 
Duffy antigen, which can sequester the ELR motif-positive CXC chemokines without 
eliciting any intracellular signals (Table 1), has been shown to suppress the 
angiogenic effects of the ELR- positive CXC chemokines [68]. Thus, the balance 
between pro-angiogenic and anti-angiogenic chemokines may determine the degree of 
tumor neovascularization. 
Chemokines have indirect roles in tumor angiogenesis by regulating the trafficking 
of several types of myeloid-derived cells including TAMs and MDSCs [22, 44]. These 
cells are recruited to tumor sites mainly by CCL2, and they promote angiogenesis by 
producing a wide variety of angiogenic factors such as VEGF, TGF-β, CXCL8, 
platelet-derived growth factor (PDGF), and MMPs such as MMP-2 and MMP-9. 
Moreover, recruited TAMs and MDSCs may acquire endothelial cell phenotypes and 
are incorporated into the newly formed vascular structure [69]. Endothelial 
cell-derived ELR-positive CXC chemokines, especially CXCL6, induce angiogenesis 
in gastrointestinal cancer by recruiting neutrophils [70]. 
 
Fibroblasts 
Fibroblasts present in tumor tissues are designated as cancer-associated fibroblasts 
(CAFs). These fibroblasts are attracting increasing attention as producers of 
tumor-promoting molecules such as TGF-β, FGF, hepatocyte growth factor (HGF), 
and EGF [71]. The proposed cellular sources of CAFs include locally resident 
fibroblasts, cells undergoing EMT, cells undergoing endothelial-mesenchymal 
transition (EndMT), or bone marrow (BM)-derived mesenchymal stem cells (MSCs) 
[72]. In a mouse gastric cancer model, it is estimated that BM-derived MSCs can 
contribute as much as 25 % to the CAF population [73]. Conversely, in a mouse lung 
metastasis model, BM-derived cells do not significantly contribute to fibroblast 
accumulation in lungs [74]. 
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In a mouse gastric cancer model, CXCL12 expression was found to be enhanced 
together with enhanced fibrosis in tumor sites [73]. Because MSCs express CXCR4 
and CXCR7, and migrate to their ligand, CXCL12, the CXC12-CXCR4/CXCR7 axis 
may regulate the accumulation of fibroblasts and consequent fibrosis development 
[72]. Moreover, CAFs present in various types of cancer produce abundant CXCL12, 
which in turn promotes the angiogenic, proliferative, and migratory properties of 
tumor cells. CAFs produce CCL2, CCL5, CCL7, CXCL8, and CXCL14 and these 
chemokines promote tumor progression mainly by enhancing the motility of tumor 
cells [72]. 
In a mouse lung metastasis model, HGF-expressing fibroblasts were found to be 
increased in the lungs [74]. Lung fibroblasts express CCR5, and genetic deletion of 
CCR5 or its ligand, CCL3, attenuates intrapulmonary lung metastasis formation 
together with reduced fibroblast accumulation and HGF expression [74] (Figure 2). 
When activated, hepatic stellate cells (HSCs) express α-smooth muscle actin 
(α-SMA), a marker of myelofibroblasts. α-SMA-positive HSCs secrete CXCL12, just 
as CAFs do [75]. Moreover, in a mouse liver metastasis model, tumor-derived CCL2 
was found to induce the accumulation of α-SMA-positive HSCs to accumulate at 
tumor sites and the expression of MMP-2. Genetic deletion of CCR2 markedly 
attenuates tumor formation with reduced HSC accumulation and MMP-2 expression 
[76]. Thus, CCR2-mediated signals may regulate the trafficking and functions of 
HSCs in tumorigenesis. 
 
Concluding Remarks 
Cancer-related inflammation denotes the association of inflammation with tumor 
development and progression. Inflammatory responses consist of leukocyte 
infiltration, neovascularization, and fibrosis. Chemokines were initially identified as 
mediators of the inflammatory response, capable of regulating the trafficking of 
leukocytes, but subsequent investigations revealed that chemokines also have 
profound effects on endothelial cells and fibroblasts. Thus, chemokines play crucial 
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roles in cancer-related inflammation by affecting the major components of the 
inflammatory response, namely leukocytes, endothelial cells, and fibroblasts. 
Moreover, several chemokines have direct effects on the proliferative and invasive 
properties of tumor cells. In view of the multifactorial roles of chemokines in 
tumorigenesis, the elucidation of their roles will further advance our understanding of 
the pathophysiological processes of tumor development and progression. 
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Chemokine Receptor            Chemokines                             Receptor Expression in  
Leukocytes   Epithelium   Endothelium   CAF            
CXCR1                 CXCL6, 8                        PMN             +           -           - 
CXCR2                 CXCL1, 2, 3, 5, 6, 7, 8              PMN             +           +           - 
CXCR3                 CXCL4, 9, 10, 11                Th1, NK            -           +            - 
CXCR4                 CXCL12                       Widespread          +          +            - 
CXCR5                 CXCL13                         B                 -          -            - 
CXCR6                 CXCL16                       activated T           +          -            + 
CXCR7                 CXCL12, CXCL11               Widespread          +          +            - 
Unknown                CXCL14 (acts on monocytes) 
 
CCR1                   CCL3, 4, 5, 7, 14, 15, 16, 23     Mo, Mφ, iDC, NK       +          +           - 
CCR2                   CCL2, 7, 8, 12, 13             Mo, Mφ, iDC, NK       +          +           - 
                                                     activated T, B 
CCR3                   CCL5, 7, 11, 13, 15, 24, 26, 28   Eo, Ba, Th2            -           +           - 
CCR4                   CCL2, 3, 5, 7, 22              iDC, Th2, NK, T, Mφ     -           -           -  
CCR5                   CCL3, 4, 5, 8                 Mo, Mφ, NK, Th1       +          -            + 
                                                     activated T 
CCR6                   CCL20                      iDC, activated T, B      +          -            - 
CCR7                   CCL19, 21                   mDC, Mφ, naïve T      +          -             - 
                                                      activated T 
CCR8                   CCL1, 4, 17                  Mo, iDC, Th2, Treg     -           -            - 
CCR9                   CCL25                      T                    +          -            - 
CCR10                  CCL27, 28                   activated T, Treg        +          -            - 
Unknown                CCL18 (acts on mDC and naïve T) 
 
CX3CR1                CX3CL1                     Mo, iDC, NK, Th1       +          -            - 
 
XCR1                  XCL1, 2                      T, NK                 -          -            - 
 
Miscellaneous 
Duffy antigen            CCL2, 5, 11, 13, 14, CXCL1, 2, 3, 7, 8 
D6                     CCL2, 3, 4, 5, 7, 8, 12, 13, 14, 17, 22 
 
Table 1. The human chemokine system. Leukocyte anonyms are as follows: Ba, basophil; Eo, 
eosinophil; iDC, immature dendritic cell; mDC, mature dendritic cell; Mo, monocyte; Mφ, 
macrophage; NK, natural killer cell; Th1, type I helper T cell; Th2, type II helper T cell; Treg, 
regulatory T cell. CAF, cancer-associated fibroblast. 
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Legend to Figure 
 
Figure 1. Effects of chemokines on tumor cells. 
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